• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to compounds having a structure according to formula (I), where R1 and Ar are as defined in this document, are agonists for the Toll 7 receptor type (TLR7) and can be used as adjuvants to stimulate the immune system. Some of these compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    公开号:BR112020002957A2
    申请号:R112020002957-2
    申请日:2018-08-16
    公开日:2020-08-04
    发明作者:Yam B. POUDEL；Liqi He；Sanjeev Gangwar；Shoshana L. Posy；Prasanna Sivaprakasam
    申请人:Bristol-Myers Squibb Company；
    IPC主号:
    专利说明:

    [0001] [0001] This claim claims the benefit under 35 U.S.C. $ 8119 (e) of US Provisional Order No. Series 62 / 546,195, filed on August 16, 2017; the disclosure of which is incorporated by reference. BACKGROUND OF THE INVENTION
    [0002] [0002] This invention relates to Toll 7 receptor agonists ("TLR7") and conjugates thereof, and methods for the preparation and use of these agonists and their conjugates.
    [0003] [0003] Toll-like receptors ("'TLRs") are cell surface receptors that recognize molecular patterns associated with pathogens ("PAMPs"). The activation of a TLR by binding a corresponding PAMP signals potential infection by a pathogen and stimulates the immune system to fight the infection. Humans have 11 TLRs, called TLR1 to TLR1I1.
    [0004] [0004] The activation of a TLR - TLR7 being the most studied - by an agonist can have an adjuvant effect on the action of vaccines and immunotherapy agents in the treatment of a variety of conditions in addition to infection by a real pathogen, stimulating the response immune.
    [0005] [0005] TLR7 recognizes PAMPs associated with single-stranded RNA viruses. Its activation induces the secretion of | type interferons, such as IFNa and IFNB (Lund et a /. 2004). It has two binding sites, one for single-stranded RNA ligands, such as ssSsRNA40 (Berghöfer et al. 2007) and another for guanosine (Zhang et al. 2016).
    [0006] [0006] TLRZ7 can bind to, and be activated by, synthetic guanosine agonists, such as imiquimod, resiquimod and gardiquimod,
    [0007] [0007] TLR7 synthetic agonists based on a molecular scaffold of pteridinone are also known, as exemplified by vesatolimod (Desai et al. 2015), which was in Phase 2 clinical trials. The potency of vesatolimod is reported to be 100X less than that of the corresponding purine-8-one compound, measured by IFN-a induction (Roethle et a /. 2013). NH 4
    [0008] [0008] Other synthetic TLR7 agonists are based on a purine-type scaffold, often according to formula (A): NH Xe 6 RON t Rº where R, R ', and R "are structural variables, with R" typically containing a substituted or unsubstituted aromatic or heteroaromatic ring.
    [0009] [0009] Disclosures of bioactive molecules having a purine type and their uses in the treatment of conditions such as fibrosis, inflammatory disorders, cancer or pathogenic infections include: Akinbobuyi et al. 2015b and 2016; Barberis et al. 2012; Carson et al. 2014; Ding et al. 2016, 2017a, and 2017b; Graupe et al. 2015; Hashimoto et a /. 2009; Hol- Idack et al. 2012; Isobe et al. 2009a and 2012; Jin et al. 2017a and 2017b;
    [0010] [0010] The group R "can be pyridyl: Bonfanti et al. 2015a and 2015b; Halcomb et al. 2015; Hirota et a /. 2000; Isobe et al. 2000, 2002, 2004, 2006, 2009a, 2011, and 2012 ; Kasibhatla et al. 2007; Koga-Yamakawa et al. 2013; Musmuca et a /. 2009; Nakamura 2012; Ogita et al. 2007; and Yu et al. 2013.
    [0011] [0011] Bonfanti et al. 2015b disclose TLR7 modulators in which the two rings of a purine portion are encompassed by a macrocycle: NH> XDED-os
    [0012] [0012] A TLR7 agonist can be conjugated to a partner molecule, which can be, for example, a phospholipid, a poly (ethylene glycol) ("'PEG"), or another TLR (usually TLR2). Exemplary disclosures include: Carson et a /. 2013, 2015, and 2016, Chan et a /. 2009 and 2011, Lioux et al. 2016, Maj et al. 2015, Ban et al. 2017; Vernejoul et al. 2014, and Zurawski et al. 2012. The conjugation to an antibody was also disclosed: Akinbobuyi et al. 2013 and 2015a, and Gadd et al. 2015. A frequent conjugation site is in the R "group of formula (A).
    [0013] [0013] TLR7 agonists based on a 5H-pyrrole [3,2-d] pyrimidine scaffold have also been disclosed. See Cortez et al. 2017a and 2017b, McGowan et al. 2017, and Li et al. 2018.
    [0014] [0014] Jensen et al. 2015 disclose the use of cationic lipid vehicles for the delivery of TLR7 agonists.
    [0015] [0015] Some TLR7 agonists, including resiquimod are double TLR7 / TLR8 agonists. See, for example, Beesu et al. 2017; Li- oux et al. 2016; and Vernejoul et al. 2014.
    [0016] [0016] TLR7 agonists based on a 5H-pyrrole [3,2-dpirimidine scaffold were also disclosed. See Cortez et al. 2017a and
    [0017] [0017] Complete references for the documents cited here by author or inventor and year are listed at the end of this specification. BRIEF SUMMARY OF THE INVENTION
    [0018] [0018] In one aspect, this specification provides compounds having a structure according to the formula (|) NH>
    [0019] [0019] Compounds according to formula (1) have activity as agonists of TLR7 and some of them can be conjugated for targeted delivery to a target tissue or organ of intended action. BRIEF DESCRIPTION OF THE DRAWINGS
    [0020] [0020] Figure 1 shows a scheme for preparing compounds of the present invention.
    [0021] [0021] Figure 2 and Figure 3 show schemes for preparing still other compounds of the present invention.
    [0022] [0022] Figure 4 and Figure 5 show schemes for the preparation of agonist-ligand compounds.
    [0023] [0023] Figure 6 is a representative graph showing the TLR7 agonism activity of a compound of this invention.
    [0024] [0024] "Antibody" means total antibodies and any antigen-binding fragment (i.e., "antigen-binding moiety") or single-stranded variant thereof. A total antibody is a protein that comprises at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (Vx) and a heavy chain constant region comprising three domains,
    [0025] [0025] "Antigen binding fragment" and "antigen binding portion" of an antibody (or simply "antibody portion" or "antibody fragment") means one or more fragments of an antibody that have the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody, such as (i) a Fab fragment, a monovalent fragment consisting of the V., Vn, CL domains and Cri; (li) an F (ab ') 2 fragment, a divalent fragment comprising two Fab fragments linked by a disulfide bridge in the hinge region; (ili) a Fab 'fragment, which is essentially a Fab with part of the hinge region (see, for example, Abbas et a / l., Cellular and Molecular Immunology, 6th Ed., Saunders Elsevier 2007 ); (iv) an Fd fragment consisting of the Vx and CH domains; (v) an Fv fragment consisting of the V. and Vu domains of a single arm of an antibody, (vi) a dAb fragment (Ward et a /., (1989) Nature 341: 544-546), consisting of in a Vn domain; (vii) an isolated complementarity determination region (CDR); and (vili) a nanobody, a variable region of heavy chain containing a single variable domain and two constant domains. Preferred antigen-binding fragments are Fab, F (ab ') 2, Fab', Fv and Fd fragments. Furthermore, although the two Fv fragment domains, V. and Vu, are encoded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that allows them to be produced as a single chain protein in which the V. and Vx regions pair to form modern molecules (known as single-chain Fv, or scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single chain antibodies are also included in the term "antigen-binding portion" of an antibody.
    [0026] [0026] Unless otherwise indicated - for example, by reference to linear numbering in a SEQ ID NO listing: - references to the numbering of amino acid positions in a variable region of light or heavy antibody chain (Vn or V. ) are in accordance with the
    [0027] [0027] An "isolated antibody" means an antibody that is substantially free of other antibodies with different antigen specificities (for example, an isolated antibody that specifically binds to antigen X is substantially free of antibodies that specifically bind to antigens other than antigen X). An isolated antibody that specifically binds to antigen X may, however, cross-react with other antigens, such as antigen X molecules from other species. In certain embodiments, an isolated antibody specifically binds to human X antigen and does not cross-react with other antigen X (non-human) antigens. In addition, an isolated antibody can be substantially free of other chemicals and / or cellular material.
    [0028] [0028] "Monoclonal antibody" or "monoclonal antibody composition" means a preparation of antibody molecules of unique molecular composition, which has a unique binding specificity and affinity with a specific epitope.
    [0029] [0029] "Human antibody" means an antibody that has regions
    [0030] [0030] "Human monoclonal antibody" means an antibody that has a unique binding specificity, which has variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In one embodiment, human monoclonal antibodies are produced by a hybridoma that includes a B cell obtained from a transgenic non-human animal, for example, a transgenic mouse, having a genome comprising a human heavy chain transgene and a chain transgene light fused to an immortalized cell.
    [0031] [0031] "Aliphatic" means a straight or branched non-aromatic, saturated or unsaturated hydrocarbon portion having the specified number of carbon atoms (for example, as in "C3 aliphatic", "C1-5 aliphatic "," C1-Cs aliphatic "or" C, aliphatic Cs ", the last three sentences being synonymous with an aliphatic portion with 1 to 5 carbon atoms) or where the number of carbon atoms is not explicitly specified , from 1 to 4 carbon atoms (2 to 4 carbons in the case of unsaturated aliphatic portions). A similar understanding is applied to the number of carbons in other types, as in
    [0032] [0032] "Alkyl" means a saturated aliphatic portion, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C1-C, alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, t-butyl, 1-butyl, 2-butyl, and the like. "Alkylene" means a divalent counterpart of an alkyl group, such as CH2CH2, CH2CH2CH> 2, and CH2CH2CH2CH>.
    [0033] [0033] "Alkenyl" means an aliphatic moiety having at least one carbon-carbon double bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C2-Ca alkenyl moieties include, but are not limited to, ethenyl (vinyl), 2-propenyl (all or prop-2-enyl), cis-1-propenyl, trans-1-propenyl, E- (or Z-) 2-butenyl, 3-butenyl, 1,3-butadienyl (but-1,3-dienyl) and the like.
    [0034] [0034] "Alquinyl" means an aliphatic moiety having at least one carbon-carbon triple bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C2-Ca alkynyl groups include ethinyl (acetylenyl), propargyl (prop-2-inyl), 1-propynyl, but-2-inyl, and the like.
    [0035] [0035] "Cycloaliphatic" means a non-aromatic, saturated or unsaturated hydrocarbon portion having 1 to 3 rings, each ring having 3 to 8 (preferably 3 to 6) carbon atoms. "Cycloalkyl" means a cycloaliphatic portion in which each ring is saturated. "Cycloalkenyl" means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon double bond. "Cycloalkynyl" means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, cycloaliphatic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, and adamantyl. Preferred cycloaliphatic moieties are cycloalkyl, especially cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. "Cycloalkylene" means a divalent counterpart to a cycloalkyl group.
    [0036] [0036] "Heterocycloaliphatic" means a cycloaliphatic portion in which, in at least one ring thereof, up to three (preferably 1 to 2) carbons have been replaced by a heteroatom independently selected from N, O or S, where Ne S can optionally be oxidized and N can optionally be quaternized. Preferred cycloaliphatic portions consist of a ring, with a size of 5 to 6 members. Likewise, "heterocycloalkyl", "heterocycloalkenyl" and "heterocycloalkyl" mean a cycloalkyl, cycloalkenyl or cycloalkynyl moiety, respectively, in which at least one ring has been modified. Exemplary heterocycloaliphatic moieties include aziridinyl, azetidinyl, 1,3-dioxanyl, oxetanyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl, tetrahydrothiophine, morphine, triforphine, morpholine, tyrolamine, morpholine, tetrahydrophenyl. thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothienyl, 1,4-dioxanyl, tietanyl, and the like. "Heterocycloalkylene" means a divalent counterpart of a heterocycloalkyl group.
    [0037] [0037] "Aloxy", "aryloxy", "alkylthio" and "arylthio" mean —O (alkyl), -Of (aryl), -S (alkyl), and -S (aryl), respectively. Examples are methoxy, phenoxy, methylthio and phenylthio, respectively.
    [0038] [0038] "Halogen" or "halo" means fluorine, chlorine, bromine or iodine, unless a more restricted meaning is indicated.
    [0039] [0039] "Arila" means a hydrocarbon portion having a system
    [0040] [0040] "Heteroaryl" means a portion having a mono-, bi- or tricyclic ring system (preferably 5-7 membered monocyclic) in which each ring has 3 to 7 carbon atoms and at least one ring is a ring aromatic containing from 1 to 4 heteroatoms independently selected from N, O, or S, where Ne S can optionally be oxidized and N optionally can be quantized. Such at least one heteroatom containing an aromatic ring can be fused to other types of rings (as in benzofuranyl or tetrahydroisoquinolyl) or directly linked to other types of rings (as in phenylpyridyl or 2-cyclopentylpyridyl). As an additional illustration, heteroaryl portions include pyrrolyl, furanyl, thiophenyl (thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, N-oxopyridyl, pyridin, pyridin, pyridine quinolinyl, isoquinolinyl, quinazolinyl, cinolinyl, quinozalinyl, natftiridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadi- azolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, dibenzofuranyl, dibenzofidyl, and carbazolyl. "Heteroarylene" means a divalent counterpart of a heteroaryl group.
    [0041] [0041] Where indicated that a portion may be substituted, such as using the terms "unsubstituted or substituted" or "op-
    [0042] [0042] "Arylalkyl", - "(heterocycloaliphatic) alquia", - "arylalkenyl", "arylalquininyl", "biarylalkyl" and the like means an alkyl, alkenyl or alkynyl portion, as the case may be, replaced by an aryl, heterocycloaliphatic portion, biaryl, etc., as the case may be, with the open (unmet) valence of the alkyl, alkenyl or alkaline portion, for example, as in benzyl, phenethyl, N-imidazoylethyl, N-morpholinoethyl and the like. On the other hand, "alkylaryl", "alkenylcycloalkyl" and the like mean an aryl, cycloalkyl etc. portion, as the case may be, replaced by an alkyl, alkenyl portion etc., as the case may be, for example, as in methylphenyl (tolyl) or allylcyclohexyl. "Hydroxyalkyl", "haloalkyl", "alkylaryl", "cyanoaryl" and the like mean an alkyl, aryl, etc. portion, as appropriate, replaced by one or more of the identified substituents (hydroxyl, halo, etc. as appropriate) ).
    [0043] [0043] For example, permitted substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo (especially fluorine), haloalkyl ( especially trifluoro-
    [0044] [0044] Where the portion being substituted is an aliphatic portion, preferred substituents are aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo, hydroxyl, cyano, nitro, alkoxy, -O (hydroxyalkyl), -O (haloalkyl), -O (cycloalkyl), -O (heterocycloalkyl), -O (aryl), alkylthio, arylthio, = O, = NH, = N (alkyl), = NOH, = NO (alkyl), -CO2H, -C (= O) NHOH, -C (= O) O (alkyl), -C (= O) O (hydroxyalkyl), -C (= O) NH2, -C (= O) NH (alkyl), - C (= O) N (alkyl) -, -OC (= O) (alkyl), -OC (= O) (hydroxyalkyl), -OC (= 0) O (alkyl), -OC (= O) O ( hydroxyalkyl), -OC (= O) NH2, -OC (= O) NH (alkyl), -OC (= O) N (alkyl) 2, azido, -NH>, -NH (alkyl), -N (alkyl ) ,, -NH (aryl), -NH (hydroxyalkyl), -NHC (= O) (alkyl), -NHC (= O) H, -NHC (= O) NH> 2, -NHC (= O) NH (alkyl), -NHC (= O) N (alkyl) a, -NHC (= NH) NH,>, -OSO, (alkyl), -SH, -S (alkyl), -S (aryl), -S (= O) alkyl, -S (cycloalkyl), -SO> z (alkyl), -SO2NH2, -SO2NH (alkyl), and -SO2N (alkyl) ,. More preferred substituents are halo, hydroxyl, cyano, nitro, alkoxy, -O (aryl), = O, = NOH, = NO (alkyl), -OC (= O) (alkyl), -OC (= 0) O ( alkyl), -OC (= O) NH> 2, -OC (= O) NH (alkyl), -OC (= O) N (alkyl) 2, azido, -NH2, -NH (alkyl), - N (alkyl) ,, -NH (aryl), -NHC (= O) (alkyl), -NHC
    [0045] [0045] Where the portion being replaced is a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl portion, the preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyan, nitro, alkoxy, -O ( hydroxyalkyl), -O (haloalkyl), -O (aryl), -O (cycloalkyl), -O (heterocycloalkyl), alkylthio, arylthio, -C (= O) (alkyl), -C (= O) H, - CO2H, -C (= O) NHOH, -C (= O) O (alkyl), -C (= O) O (hydroxyalkyl), -C (= O) NH> 2, -C (= O) NH (alkyl), -C (= O) N (alkyl) 2a, -OC (= O) (alkyl), -OC (= O) (hydroxyalkyl), -OC (= O0) O (alkyl), -OC (= O) O (hydroxy-alkyl), -OC (= O) NH> 2, -OC (= O) NH (alkyl), -OC (= O) N (alkyl) 2, azido, -NH > 2, -NH (alkyl), -N (alkyl) -, -NH (aryl), -NH (hydroxyalkyl), -NHC (= O) (alkyl), -NHC (= O) H, -NHC (= O) NH> 2, -NHC (= O) NH (alkyl), -NHC (= O) N (alkyl)., -NHC (= NH) NH2, -OSO,> (alkyl), -SH, -S (alkyl), -S (aryl), -S (cycloalkyl), -S (= O) alkyl, -SO> z (alkyl), -SO2NH2, -SO2NH (alkyl), and -SO2xN (alkyl) -. More preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, -O (hydroxyalkyl), -C (= O) (alkyl), -C (= O) H, -CO2H, - C (= O) NHOH, -C (= O) O (alkyl), -C (= O) O (hydroxyalkyl), -C (= O) NH2, -C (= O) NH (alkyl), -C (= O) N (alkyl) 2, -OC (= O) (alkyl), -OC (= O) (hydroxyalkyl), -OC (= O) O (alkyl), -OC (= O) O (hydroxyalkyl), -OC (= O) NH2, -OC (= O0) NH (alkyl), -OC (= O) N (alkyl) 2, -NH2, -NH (alkyl), -N (alkyl) 2 , -NH (aryl), -NHC (= O) (alkyl), -NHC (= O) H, -NHC (= O) NH> 2, -NHC (= O) NH (alkyl), -NHC (= O) N (alkyl) 2, and -NHC (= NH) NH> 2. Especially preferred are C1-Ca alkyl, cyano, nitro, halo and C1-Caalkoxy.
    [0046] [0046] Where a range is defined, as in "C1-Cs alkyl" or "5 to 10%", that range includes the end points of the range, as in C; and Cs in the first instance and 5% and 10% in the second
    [0047] [0047] Unless certain stereoisomers are specifically indicated (for example, by a bold link or traced in a relevant stereocenter in a structural formula, by representing a double bond as having the E or Z configuration in a structural formula, or using stereochemistry designation nomenclature), all stereoisomers are included in the scope of the invention, both as pure compounds and in their mixtures. Unless otherwise indicated, enantiomers, diastereomers, individual geometric isomers, and combinations and mixtures thereof are all covered by this invention.
    [0048] [0048] Those skilled in the art will appreciate that the compounds may have tautomeric forms (for example, keto and enol forms), resonance forms and zwitterionic forms equivalent to those represented in the structural formulas used here and that the structural formulas cover such tautomeric forms , resonance or zwitterionics.
    [0049] [0049] "Pharmaceutically acceptable ester" means an ester that hydrolyzes in vivo (for example, in the human body) to produce the parent compound or a salt thereof or that has per se activity similar to that of the parent compound. Suitable esters include C1-Cs alkyl, C2-Cs alkenyl or C2-C5 alkynyl, especially methyl, ethyl or n-propyl.
    [0050] [0050] "Pharmaceutically acceptable salt" means a salt of a compound suitable for pharmaceutical formulation. When a compound has one or more basic groups, the salt can be an acid addition salt, such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), iodide, nitra - to, hydrochloride, lactate, methyl sulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, tosylate and the like. When a compound has one or more acidic groups, the salt can be a salt, such as a calcium salt, potassium salt, magnesium salt, melamine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, etc. Polymorphic crystalline forms and solvates are also included in the scope of this invention.
    [0051] [0051] In the formulas of this invention, a wavy line (= -) across a bond or an asterisk (*) at the end of the bond indicates a covalent bond site. For example, a statement that R is
    [0052] [0052] In the formulas of this invention, a bond that crosses an aromatic ring between two carbons means that the group attached to the bond can be located in any of the aromatic ring positions made available by removing the hydrogen that is implicitly there. By way of illustration, the formula P NH2 LO represents e. O or Me 'D Me; Me NH,
    [0053] [0053] In another illustration, Dx
    [0054] [0054] In general, tautomeric structures were presented here in the form of enol, for reasons of consistency and convenience.
    [0055] [0055] Those skilled in the art will appreciate that they could also be presented in equivalent keto form and that the two tautomers are equivalent. TLR7 agonists
    [0056] [0056] R 'in formula (1) is preferably n-BuO, n-BuNH, EtoO, MeO, or MeOCH2CH2O; more preferably, n-BuO or Me-OCH2CH20O; and most preferably, n-BuO.
    [0057] [0057] In a modality, a compound according to the formula | is represented by the formula (la), where R 'is n-BuO or Me-OCH2CH20O, preferably n-BuO: NH2 (la) Ds
    [0058] [0058] Examples of compounds according to the formula (la) include: NH2 (la-01) NH2 (la-02) NOSAN, OE 1a ED neo "Né o”
    [0060] [0060] In another modality, a compound according to the formula | is represented by the formula (lb), where R 'is n-BuO or Me-OCH2CH20O, preferably n-BuO:
    [0062] [0062] Table B presents biological activity data for compounds (lb) disclosed in this document. and TR
    [0063] [0063] In another modality, a compound according to the formula | is represented by the formula (lb), where R 'is n-BuO or Me-OCH2CH20O, preferably n-BuO: NH (lo) Edo
    [0064] [0064] Examples of compounds according to the formula (lc) include: NHz (Ic-01) NHz (10-02)
    [0065] [0065] Table C presents biological activity data for compounds (lc). RE E
    [0066] [0066] In formulas (1), (la), (Ib), and (Io), preferably D is He R is different from H.
    [0067] [0067] Specific examples of —-N (Rº) (Rº) that can be used in compounds of formulas (1), (la), (Ib) and (Ic) include:
    [0068] [0068] The TLR7 agonists disclosed herein can be delivered to the site of action intended by the localized administration or by targeted delivery in conjunction with a targeting portion. Preferably, the targeting portion is an antibody or antigen-binding portion of it and its antigen is found in the intended action site, for example, a tumor-associated antigen, if the intended site of action is a tumor ( cancer). Preferably, the tumor-associated antigen is expressed uniquely or overexpressed by the cancer cell as compared to a normal cell. The tumor-associated antigen can be located on the surface of the cancer cell or secreted by the surrounding cancer cell.
    [0069] [0069] In one aspect, a conjugate is provided that comprises a compound of this invention and a linker, represented by the formula (Il) [D (XP) to (C) c (XE) nlmZ (11) where Z is a targeting portion, D is an agonist of this
    [0070] [0070] When binding to a target tissue or cell, where its antigen or receptor is located, Z directs the conjugate there. Cleavage of group C in the target tissue or cell releases D to exert its effect locally. In this way, accurate delivery of D is achieved at the intended action site, reducing the required dose. In addition, D is normally biologically inactive (or significantly less active) in its conjugated state, thereby reducing off-target effects.
    [0071] [0071] As reflected by the subscript m, each Z can be combined with more than one D, depending on the number of sites that Z has available for conjugation and the experimental conditions employed. Those skilled in the art will understand that, although each individual Z is conjugated to an integer number of Ds, a conjugate preparation can analyze a non-integer ratio from D to Z, reflecting a statistical average. This ratio is referred to as the replacement ratio ("SR") or the drug-antibody ratio ("DAR"). Z targeting portion
    [0072] [0072] Preferably, the Z targeting portion is an antibody. For convenience and brevity and not by limitation, the detailed discussion in this description of Z and its conjugates is written in the context of being an antibody, but those skilled in the art will understand that other types of Z can be conjugated, mutatis mutandis. For example, conjugates with folic acid as the targeting moiety can target cells that have the folate receptor on their surfaces (Leamon et al., Cancer Res. 2008, 68 (23), 9839). For the same reasons, the detailed discussion in this description is written primarily in terms of a 1: 1 ratio from Z to D (m = 1).
    [0073] [0073] Antibodies that can be used in conjugates of this invention include those that recognize the following antigens: mesothelin, prostate specific membrane antigen (PSMA), CD19, CD22, CD30, CD70, B7H3, B7H4 (also known as OB8E), protein tyrosine kinase 7 (PTK7), glypican-3, RG1, fucosyl-GM1, CTLA-4 and CD44. The antibody can be animal (e.g., murine), chimeric, humanized or, preferably, human. The antibody is preferably monoclonal, especially a human monoclonal antibody. The preparation of human monoclonal antibodies against some of the antigens mentioned above is disclosed in Korman et a /., US 8,609,816 B2 (2013; B7H4, also known as 08E; in particular antibodies 2A7, 1611 and 2F9); Rao-Naik et al., 8,097,703 B2 (2012; CD19; in particular antibodies 5G7, 13F1, 46E8, 21D4, 21D4a, 47G4, 27F3 and 3C10); King et al., US 8,481,683 B2 (2013; CD22; in particular antibodies 12C5, 19A3, 16F7 and 23C6); Keler et al., US 7,387,776 B2 (2008; CD30; in particular antibodies 5F11, 2H9 and 17G1); Terrett et al., US 8,124,738 B2 (2012; CD70; in particular antibodies 2H5, 10B4, 8B5, 18E7 and 69A7); Korman et al., US 6,984,720 B1 (2006; CTLA-4; in particular antibodies 10D1, 4B6 and 162); Korman et a /., US 8,008,449 B2 (2011; PD-1; on particular antibodies 17D8, 2D3, 4H1, 5C4, 4A11, 7D3 and 5F4); Huang et a /., US 2009/0297438 A1 (2009; PSMA. In particular antibodies 1C3, 2A10, 2F5, 2C6); Cardarelli et al., US 7,875,278 B2 (2011; PSMA; on particular antibodies 4A3, 7F12, 8C12, 8A11,
    [0074] [0074] In addition to being an antibody, Z can also be an antibody fragment (such as Fab, Fab ', F (ab') 2a, Fd, or Fv) or antibody mimetic, such as an affibody, a domain antibody (dAb), a nanobody, a single body, a DARPin, an anticalin, a versibody, a duocalin, a lipocalin or an avimer.
    [0075] [0075] Any one of several different reactive groups in Z can be a conjugation site, including e-amino groups in lysine residues, pendant carbohydrate moieties, carboxylic acid groups in aspartic or glutamic acid side chains , cysteine-cysteine disulfide groups and thiol cysteine groups. For analyzes of reactive groups of antibodies suitable for conjugation, see, for example, Garnett, Adv. Drug Delivery Rev. 2001, 53, 171-216 and Dubowchik and Walker, Pharmacology & Therapeutics 1999, 83, 67-123, the disclosures tions of which are incorporated herein by reference.
    [0076] [0076] Most antibodies have multiple lysine residues, which can be conjugated through their e-amino groups by
    [0077] [0077] A thiol group (-SH) on the side chain of a cysteine can be used to form a conjugate by several methods. It can be used to form a disulfide bond between it and a thiol group in the linker. Another method is by adding Michael to a maleimide group in the linker.
    [0078] [0078] Typically, although antibodies have cysteine residues, they do not have free thiol groups, because all of their cysteines are involved in intra- or interchain disulfide bonds. To generate a free thiol group, a native disulfide group can be reduced. See, for example, Packard et al., Biochemistry 1986, 25, 3548; King et al., Cancer Res. 1994, 54, 6176; and Doronina et al., Nature Biotechnol. 2003, 21, 778. Alternatively, a cysteine having a free -SH group can be introduced by mutating the antibody, replacing one cysteine with another amino acid or inserting one into the polypeptide chain. See, for example, Eigenbrot et al /., US 7,521,541 B2 (2009); Chilkoti et al., Bioconjugate Chem. 1994, 5, 504; Urnovitz et al., US
    [0079] [0079] As noted above, the linker comprises up to three elements: a cleavable group C and optional spacers X and Xº.
    [0080] [0080] Group C is cleavable under physiological conditions. Preferably, it is relatively stable while the conjugate is circulating in the blood, but is rapidly cleaved when the conjugate reaches its intended site of action.
    [0081] A preferred group C is a peptide that is selectively cleaved by a protease within the target cell, as opposed to a protease in the serum. Typically, the peptide comprises from 1 to 20 amino acids, preferably from 1 to 6 amino acids, more preferably from 2 to 3 amino acids. The amino acid (s) can be natural and / or unnatural α-amino acids. The natural amino acids are those encoded by the genetic code, as well as the amino acids derived from it, for example, hydroxyproline, y-carboxyglutamate, citrulline and O-phosphoserine. In this description, the term "amino acid" also includes amino acid analogs and mimetics. The analogues are composed with the same general structure of HAN (R) CHCO> 2H as a natural amino acid, except that the R group is not found among the natural amino acids. Examples of analogues include homoserine, norleucine, methionine-sulfoxide and methionine-methylsulfonium. An amino acid mimetic is a compound that has a different structure from the general chemical structure of an α-amino acid, but works similarly to one. The amino acid can be from the "L" stereochemistry of genetically encoded amino acids, as well as from the "D" enantiomeric stereochemistry.
    [0082] [0082] Preferably, C contains an amino acid sequence which is a cleavage recognition sequence for a protease. Many cleavage recognition sequences are known in the art. See, for example, Matayoshi et al. Science 247: 954
    [0083] [0083] A group C can be chosen so that it is cleaved by a protease present in the extracellular matrix in the vicinity of a cancer, for example, a protease released by nearby agonizing cancer cells or a tumor-associated protease secreted by cancer cells. Exemplary tumor-associated extracellular proteases are plasmin, matrix metalloproteases (MMP), timet oligopeptidase (TOP) and CD10. See, for example, Trouet et al., US 7,402,556 B2 (2008); Dubois et al., US 7,425,541 B2 (2008); and Bebbington et a /., US 6,897,034 B2 (2005). Cathepsin D, normally a lysosomal enzyme found inside cells, is sometimes found in the vicinity of a tumor, possibly released by agonizing cancer cells.
    [0084] [0084] For conjugates designed to be by an enzyme, C preferably comprises an amino acid sequence selected for cleavage by proteases, such as cathepsins B, C, D, H, L and S, especially cathepsin B. Cathepsin cleavable peptides Exemplary Bs include Val-Ala, Val-Cit, Val-Lys, Lys-Val-Ala, Asp-Val-Ala, Val-Ala, Lys-Val-Cit, Ala-Val-Cit, Val-Gly, Val-Glh and Asp-Val-Cit. (Here, amino acid sequences are written in the N to C direction, as in HoN-AA -AA'-CO> 2H, unless the context clearly indicates otherwise.) See Dubowchik et al., Biorg. Med. Chem. Lett. 1998, 8, 3341; Dubowchik et al., Bioorg. Med. Chem. Lett. 1998, 8, 3347; and Dubowchik et a /., Bioconjugate Chem. 2002, 13, 855; the disclosures of which are incorporated by reference.
    [0085] [0085] Another enzyme that can be used to cleave peptidyl ligands is legumaine, a lysosomal cysteine protease that preferably cleaves in Ala-Ala-Asn.
    [0086] [0086] In one embodiment, Group C is a peptide that comprises a sequence of two amino acids AA -AA 'where AA' is lysine, arginine or citrulline and AA is phenylalanine, valine, alanine, leucine or isoleucine. In another modality, C consists of a sequence of one to three amino acids, selected from the group consisting of Val-Cit, Al-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys , Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser and Glu. More preferably, it is a two to three amino acid peptide from the previous group.
    [0087] [0087] The preparation and design of cleavable groups C consisting of a single amino acid are disclosed in Chen et a /., US 8,664,407 B2 (2014), the disclosure of which is hereby incorporated by reference.
    [0088] [0088] Group C can be linked directly to Z or D; that is, X spacers or XP, as the case may be, are absent.
    [0089] [0089] When present, spacer X provides spatial separation between C and Z, so that the former does not interfere sterically with the antigen binding by the latter or the latter does not interfere sterically with the cleavage of the former. In addition, the X it can be used to impart greater solubility or reduced aggregation properties to conjugates. An X spacer it can comprise one or more modular segments, which can be assembled in any number of combinations. Examples of suitable segments for an X spacer are:
    [0090] [0090] The XP spacer, if present, provides spatial separation between C and D, so that the latter does not interfere sterically or electronically with the cleavage of the former. The XP spacer can also serve to introduce additional molecular weight and chemical functionality into a conjugate. Generally, additional functionality and mass will affect the serum half-life and other properties of the conjugate. Thus, through the careful selection of spacer groups, the serum half-life of a conjugate can be modulated. The XP spacer can also be assembled from modular segments, analogous to the description above for the Xº spacer.
    [0091] [0091] The Xº spacers and / or Xº , when present, preferably provide a linear separation of 4 to 25 atoms, more preferably 4 to 20 atoms, between Z and C or De C, respectively.
    [0092] [0092] The ligand can perform other functions, in addition to covalently binding the antibody and the drug. For example, the linker may contain a group of poly (ethylene glycol) ("(PEG"). Since the conjugation step typically involves coupling a drug-linker to an antibody in an aqueous medium, a group PEG can improve the aqueous solubility of the drug-ligand, in addition, a PEG group can improve the solubility or reduce aggregation in the resulting ADC. When a PEG group is present, it can be incorporated into the X Spacer of XP, or The number of repeat units in a PEG group can be 2 to 20, preferably between 4 and 10.
    [0093] [0093] Any spacer X or XP, or both, can comprise an auto-immolating portion. A self-immolating portion is a portion that (1) is linked to C and Z or D, and (2) has a structure such that the click
    [0094] [0094] Exemplary self-immolating portions (i) - (v) attached to a hydroxyl or amino group of D are shown below: (O) p (ii) a o (iii) a o o A 7 NO, o O o O AAA Aa PS RS (vi) a b of ms>, Mw. "º po indo: OH º 5 and Ss: à: o OH: í:::; COM (vi) a b c Ne AA,“ O. uv 4 HR
    [0095] [0095] The self-immolating portion is the structure between dashed lines a and b (or dashed lines b and c), with adjacent structural features shown to provide context. The self-insulating portion (s) (i) and (v) are linked to a D-NH,> (i.e., the conjugation is through an amino group), while the self-immolating portions (ii), (iii) and (iv) are linked to a D-OH (that is, the conjugation is through a hydroxyl or carboxyl group). Cleavage of the bond on the dotted line b by an enzyme - a peptidase in the instance of structures (i) - (v) and a B-glucuronidase in the instance of structure (vi) - initiates a self-immolating reaction sequence that results in cleavage of the connection on the dotted line a and the consequent release of D-OH or D-NH> z, as appropriate. By way of illustration, the auto-immolation mechanisms for structures (i) and (iv) are shown below: O) o DA o Do Qu H O H AAA H -CO, pNH2 N N
    [0096] [0096] In other words, the cleavage of a first chemical bond in a part of a self-immolating group initiates a sequence of steps that results in the cleavage of a second chemical bond - that which connects the self-immolating group to the drug - in a different part self-immolating group, thus releasing the drug.
    [0097] [0097] In some cases, self-immolating groups can be used in tandem, as shown in the structure (vii). In this case, cleavage on the dotted line c triggers the self-immolation of the portion between the dotted lines b and c by a 1.6-elimination reaction, followed by autoimolation of the portion between the dotted lines a and b by a cyclization-elimination reaction. For additional disclosures about self-immolating portions, see Carl et al., J. Med. Chem. 1981, 24, 479; Carl et al., WO 81/01145 (1981); Dubowchik et al., Pharmacology & Therapeutics 1999, 83, 67; Firestone et a /., US 6,214,345 B1 (2001); Toki et al., J. Org. Chem. 2002, 67, 1866; Doronina et al., Nature Biotechnology 2003, 21, 778 (erratum, p. 941); Boyd et al., US 7,6916,962 B2; Boyd et al., US 2008/0279868 A1; Sufi et al., WO 2008/083312 A2; Feng, US 7,375,078 B2; Jeffrey et al., US 8,039,273; and Senter et al., US 2003/0096743 A1; the disclosures of which are incorporated by reference.
    [0098] [0098] In another embodiment, Z and D are linked by a non-cleavable link, that is, C is absent. D metabolism eventually reduces the ligand to a small attached portion that does not interfere with the biological activity of D. Conjugation Techniques
    [0099] [0099] TLR7 agonist conjugates disclosed in this document are preferably produced, first, by preparing a compound comprising D and ligand (XP) to (C). (Xº) s (where XP, C, X º, a, b, and c are as defined for formula (II)) to form the drug-binding compound represented by formula (Ill): D- (XP) to (C) c (XE) 5-R $ * (111) where R * 'is a functional group suitable for reacting with a complementary functional group in Z to form the conjugate. Examples of suitable Rº * groups include amino, azide, thiol, cyclooctin,
    [00100] [00100] —Preferably, the reactive functional group -Rº * is -NH>, -OH, -CO> 2H, -SH, maleimido, cyclooctin, azido (-N3), hydroxylamino (-ONH> 2) or N -hydroxysuccinimide. Especially preferred functional groups -R% 'are: o o CC) Ee. Fox), FO o-NH> Ar Il. or NH. Ó Ó CD
    [00101] [00101] “An -OH group can be esterified with a carboxy group in the antibody, for example, in a side chain of glutamic or aspartic acid.
    [00102] [00102] “A -CO> 2H group can be esterified with an -OH group or amidated with an amino group (for example, in a lysine side chain) in the antibody.
    [00103] [00103] An N-hydroxysuccinimide group is functionally an activated carboxyl group and can be conveniently amidated by reaction with an amino group (for example, lysine).
    [00104] [00104] A maleimide group can be conjugated to a -SH group in the antibody (for example, from cysteine or from chemical modification of the antibody to introduce a sulfhydryl functionality), in a Michael addition reaction.
    [00105] [00105] When an antibody does not have an -SH cysteine available for cojugation, an e-amino group on the side chain of a lysine residue can be reacted with 2-iminothiolane or N-succinimidyl-3- (2-pyridylditium) | propionate ("SPDP") to introduce a free thiol group (-SH) - creating a cysteine substitute, so to speak. The thiol group can react with a maleimide or other nucleophilic acceptor group to effect the conjugation. The mechanism is illustrated below with 2-iminothiolane.
    [00106] [00106] Typically, a thiol level of two to three thiols per antibody is reached. For a representative procedure, see Cong et al., US 8,980,824 B2 (2015), the disclosure of which is incorporated herein by reference.
    [00107] [00107] In a reverse arrangement, a Z antibody can be modified with N-succinimidyl 4- (maleimidomethyl) -cyclohexanecarboxylate ("SMCC") or its sulphonated sulfo-SMCC variant, both available in Sigma-Aldrich, to introduce a maleimide group at the same. Then, the conjugation can be carried out with a drug-linker compound having a -SH group on the linker.
    [00108] [00108] “An alternative conjugation method employs copper-free" click chemistry ", in which an azide group adds a forced cyclooctin to form a 1,2,3-triazole ring. See, for example, Agard et al., J. Amer. Chem. Soc. 2004, 126, 15046; Best, Biochemistry 2009, 48, 6571, the disclosures of which are hereby incorporated by reference. Azide can be located in the antibody and cyclooctin in the drug-ligand portion, or vice versa. A preferred cyclooctin group is di-benzocyclooctin (DIBO). Various reagents that have a DIBO group are available from Invitrogen / Molecular Probes, Eugene, Oregon. The reaction below illustrates the chemical click conjugation for the case where the DIBO group is linked to the antibody (Ab): & Q 2% A Ab NA AS ex + | J - “A. í [Drug] - / Ligand] The [Drug] -! L / gante! O) "Conjugate
    [00109] [00109] Yet another conjugation technique involves introducing an unnatural amino acid into an antibody, with the unnatural amino acid providing functionality for conjugation to a reactive functional group in the drug moiety. For example, the unnatural amino acid p-acetylphenylalanine can be incorporated into an antibody or other polypeptide, as taught in Tian et al., WO 2008/030612 A2 (2008). The p-acetylphenylanine ketone group can be a conjugation site by forming an oxime with a hydroxylamino group in the linker-drug moiety. Alternatively, the unnatural amino acid p-azidophenylalanine can be incorporated into an antibody to provide an azide functional group for conjugation via click chemistry, as discussed above. Non-natural amino acids can also be incorporated into an antibody or other polypeptide using cellless methods, as taught in Goerke et al., US 2010/0093024 A1 (2010) and Goerke et al., Biotechnol. Bioeng. 2009, 102 (2), 400-416. The above disclosures are incorporated herein by reference. Thus, in one embodiment, an antibody that is used to produce a conjugate has one or more amino acids replaced by an unnatural amino acid, which is preferably p-acetylphenylala-
    [00110] [00110] Yet another conjugation technique uses the enzyme transglutaminase (preferably, bacterial transglutaminase from Streptoyces mobaraensis or BTG), by Jeger et al., Angew. Chem. Int. Ed. 2010, 49, 9995. BTG forms an amide bond between the side chain carboxamide of a glutamine (the amine acceptor) and an alkylene amino amino group (the amine donor), which can be, for example, for example, the e-amino group of a lysine or a 5-amino-n-pentyl group. In a typical conjugation reaction, the glutamine residue is located in the antibody, while the alkyleneamino group is located in the linker-drug moiety, as shown below ::> Q. . BTG Gnm (en-E-nH + —HNligsntel IFámacol—— o Gnmtenhl NiLigante] - [Drug) Conjugated
    [00111] [00111] The positioning of a glutamine residue in a polypeptide chain has a great effect on its susceptibility to BTG-mediated transamidation. None of the glutamine residues in an antibody is normally a substrate for BTG. However, if the antibody is deglycosylated - the glycosylation site being asparagine 297 (N297; EU index numbering, as established in Kabat et a / l., "Sequences of proteins of immunological interest", 5th ed., Pub. No. 91-3242, US Dept. Health & Human Services, NIH, Bethesda, Md, 1991; hereinafter "Kabat") of the heavy chain - the glutamine 295 (Q295) in the surroundings becomes susceptible to BTG. An antibody can be deglycosylated enzymatically by treatment with PNGase F (Peptide-N-Glycosidase F). Alternatively, an antibody can be free of synthesized glycoside by introducing an N297A mutation into the constant region, to eliminate the N297 glycosylation site. In addition, it has been shown that an N297Q substitution not only eliminates glycosylation, but also introduces a second glutamine residue (at position 297) which is also an amine acceptor. Thus, in one embodiment, the antibody is deglycosylated. In another modality, the antibody has a replacement for N297Q. Those skilled in the art will appreciate that deglycosylation by post-synthesis modification or by the introduction of an N297A mutation generates two BTG-reactive glutamine residues per antibody (one per heavy chain, at position 295), while an antibody with a N297Q substitution will have four BTG-reactive glutamine residues (two per heavy chain, at positions 295 and 297).
    [00112] [00112] An antibody can also become susceptible to BTG-mediated conjugation by introducing a peptide containing glutamine, or "tag", as taught, for example, in Pons et al., US 2013/0230543 A1 ( 2013) and Rao-Naik et a /., WO 2016/144608 A1.
    [00113] [00113] In a complementary approach, the BTG substrate specificity can be altered by varying its amino acid sequence, so that it becomes able to react with glutamine 295 in an unmodified antibody, as taught in Rao-Naik et al ., WO 2017/059158 A1 (2017).
    [00114] [00114] Although the most frequently available bacterial transglutaminase is that of S. mobaraensis, the transglutaminase of other bacteria, with slightly different substrate specificities, can be considered, such as Streptoverticillium lakanum transglutaminase (Hu et al. , US 2009/0318349 A1 (2009), US 2010/0099610 A1 (2010) and US 2010/0087371 A1 (2010)).
    [00115] [00115] The TLR7 agonists of the present invention having a primary or secondary alkyl amine are particularly suitable for use in conjugates, since the secondary amine provides a functional group for coupling the ligand. An example of such an TLR7 agonist-linker compound is compound 19, which contains an enzymatically cleavable linker. Figure 4 shows a scheme according to which compound 19 can be prepared.
    [00116] [00116] An example of a TLR7 agonist-linker compound that contains a non-enzymatically cleavable linker is compound 21. Figure 5 shows a scheme for synthesizing compound 21.
    [00117] [00117] Both compounds 19 and 21 contain a primary alkylamino group, making them susceptible to conjugation with transglutaminase. A suitable conjugation procedure is described in the Examples below.
    [00118] [00118] Conjugation can also be carried out using the enzyme Sortase A, as taught in Levary et al., PLoS One 2011, 6 (4), e18342; Proft, Biotechnol. Lett. 2010, 32, 1-10; Ploegh et al, WO 2010/087994 A2 (2010); and Mao et al., WO 2005/051976 A2 (2005). The Sortase A recognition motif (typically LPXTG, where X is any natural amino acid) may be located in the Z ligand and the nucleophilic acceptor motif (typically GGG) may be the Rº * group in the formula (Ill), or vice versa .
    [00119] [00119] - By applying the techniques described above, TLR7 agonist conjugates, such as those shown below, can be prepared: TED H Ç 9 q 9 ORI TCE E Te o 22 NH>
    [00120] [00120] The attachment of a poly (ethylene glycol) (PEG) chain to a drug ("PEGylation") can improve the pharmacokinetic properties of the latter. The circulating half-life of the drug is high, sometimes above an order of magnitude, concomitantly reducing the dosage necessary to achieve the desired therapeutic effect. PEGylation can also decrease the metabolic degradation of a drug and reduce its immunogenicity. For a review, see Kolate et al., J. Controlled Release 2014, 192, 167.
    [00121] [00121] Initially, PEGylation was applied to biological drugs. As of 2016, more than ten PEGylated biological products were approved. Turecek et al., J. Pharmaceutical Sci. 2016, 105, 460. More recently, stimulated by the successful application of the concept to biological products, attention has turned to its application to small molecule drugs. In addition to the benefits mentioned above, PEGylated small molecule drugs may have greater solubility and cause less toxic effects. Li et al. Prog. Polymer Sci. 2013, 38, 421.
    [00122] [00122] The compounds disclosed herein can be PEGylated. When a compound has an aliphatic hydroxyl or a primary or secondary aliphatic amine, as in the case of compound 6 (Figure 1) or la-05 (arrows), it can be PEGylated through an ester, amide, carbonate or carbamate group with a carboxy-containing PEG molecule using conventional techniques, such as dicyclohexylcarboniimide, HATU, N-hydroxysuccinimide esters etc. Several other methods for the PEGylation of pharmaceutical molecules are disclosed in Alconcel et al., Polymer Chem. 2011, 2, 1442, the disclosure of which is incorporated herein by reference. NH NH2 (la-05)
    [00123] [00123] If desired, a TLR7 agonist disclosed herein can be PEGylated by means of an enzymatically cleavable ligand comprising a self-immolating portion, to allow the release of the non-PEGylated agonist in a designed manner. In addition, PEGylation can be combined with conjugation to a protein, such as an antibody, if the molecule containing PEG has a suitable functional group, such as an amine, for binding to the protein. The protein can provide an additional therapeutic function or, if an antibody, it can provide a targeting function. These concepts are illustrated in the following reaction sequence, where TLR7-NH-R generically represents a TLR7 agonist:
    [00124] [00124] In the above reaction sequence, the dipeptide valine-citrulline (Val-Cit) is cleavable by the enzyme cathepsin B, with a p-amino-benzyl oxycarbonyl group (PABC) serving as a self-immolating spacer. The functional group for conjugation is an amine group, which is temporarily protected by an Fmoc group. The conjugation is carried out by the enzyme transglutaminase, with a side chain of glutamine (Gln) acting as acyl acceptor. The subscript x, representing the number of PEG repeat units, can vary widely, depending on the purpose of PEGylation, as discussed below. For some purposes, x may be relatively small, such as 2, 4.8, 12 or 24. For other purposes, x is large, for example, between 45 and 910.
    [00125] [00125] Those skilled in the art will understand that the sequence is illus-
    [00126] [00126] “When the compound does not have aliphatic hydroxyl or primary or secondary aliphatic amine, as in the case of compound 7 (Figure 1), it can still be PEGylated in the aromatic amine (arrow). A method for PEGuilation in this position is disclosed by Zarraga, US 2017/0166384 A1 (2007), the disclosure of which is incorporated herein by reference.
    [00127] [00127] In some embodiments, it may be desirable to have several PEGylated agonists attached to a single molecule. For example, four PEGylated arms can be constructed of pentaerythritol (C (CH20H) a) and a TLR7 agonist can be attached to each PEGylated arm. See Gao et a /., US 2013/0028857 A1 (2013), the disclosure of which is incorporated herein by reference.
    [00128] [00128] To modulate the pharmacokinetics, it is generally preferable that the PEG portion has a formula weight between about 2 kDa (corresponding to about 45 repeat units of (CH2CH20)) and between about 40 kDa (corresponding to about 910 (CH2CH20O) repeat units), more preferably, between about 5 kDa and about 20 kDa. That is, the range of the subscript x in the formulas above is about 45 to about 910. It should be understood that the PEG compositions are not 100% homogeneous, but exhibit a molecular weight distribution. Thus, a reference to, for example, "20kDa PEG" means PEG with an average molecular weight
    [00129] [00129] PEGUylation can also be used to improve the agility of an agonist. In such cases, a shorter PEG chain can be used, for example, comprising 2, 4, 8, 12 or 24 repeating units. EXAMPLES
    [00130] [00130] The practice of this invention can be better understood by reference to the following examples, which are provided by way of illustration and not by way of limitation. Example 1 - Synthesis of compounds of formula (la)
    [00131] [00131] This example and Figure 1 refer to the synthesis of compounds according to the formula (la).
    [00132] [00132] A suspension of pyrazine-2,5-dicarboxylic acid 1 (59, 29.7 mmoles) and HCI (1.25 M in MeOH, 50 ml, 62.5 mmoles) was stirred at 60 ° C for 20 h, after which the reaction was completed. The reaction mixture was concentrated on a rotary evaporator. The crude product was suspended in NaHCO; saturated, extracted with 10% MeOH in dichloromethane (DCM, 3x150 ml). The combined organic extracts were dried with Na2SO4; filtered and concentrated to generate dimethyl pyrazine-2,5-dicarboxylate (4.37 g, 22.28 mmol, 74.9% yield). LCMS ESI: calculated for CgãHgN2O04 = 197.0 (M + H *), found 197.0 (M + H *).
    [00133] [00133] A stirred suspension of dimethyl pyrazine-2,5-dicarboxylate (4.32 g, 22.02 mmoles) in MeOH (103 ml) and DCM (44.0 ml) was treated with NaBHa (0.833 g, 22.02 mmoles) at 0ºC. After 1 h, LCMS indicated 70% conversion with the main mono-alcohol product and the lower bis-alcohol product. More NaBHa (100 mg, 4.34 mmoles) was added at 0ºC and stirring continued for another 45 min. No further starting material was detected by LCMS. The reaction mixture was quenched by slowly adding half-saturated NH.CI and extracted with EtOAc (3x100 ml). The combined organic extracts were dried over Na2SO2, filtered and concentrated. The crude product was purified on a 249 silica column, eluted with 20% MeOH in DCM. The desired fractions were concentrated to generate methyl 5- (hydroxymethyl) pyrazine-2-carboxylate (2.43 g, 14.45 mmol, 65.6% yield). LCMS ESI: calculated for C7rHgN2O3 = 169.1 (M + H *), found 169.0 (M + H *).
    [00134] [00134] A solution of methyl 5- (hydroxymethyl) pyrazine-2-carboxylate (1.65 g, 9.81 mmoles) in tetrahydrofuran (THF, 49.1 ml) was treated with triphenylphosphine (3.09 g , 11.78 mmoles), followed by N-bromosuccinimide (NBS, 2.096 g, 11.78 mmoles) at room temperature (RT). After stirring for 90 min, the reaction was completed. After abrupt cooling with water and extraction with EtOAc (3x50 ml), the combined organic extracts were dried over Na2SO2, filtered and concentrated. The crude product was purified on a column of silica 40, eluted with EtOAc: Hexane (0-100% gradient). The desired fractions were concentrated and generated compound 2 (1.28 g, 5.54 mmoles, 56.5% yield). LCMS ESI: calculated for C7H; BrN2O2 = 230.0, 232.0 (M + H *), found 230.9, 232.9 (M + H *).
    [00135] [00135] To a suspension of compound 3 in trifluoroacetic acid (TFA, CAS Reg. No. 866268-31-7, prepared according to WO 2011/049815 A1, 1.824 g, 5.19 mmol) and cesium carbonart ( 5.42 9, 16.62 mmoles) in DMF (20 ml) was added to compound 2 (1.29, 5.19 mmoles). The reaction mixture was stirred at RT for 1 h, after which the reaction was completed. After abrupt cooling with water, the resulting solid was collected by filtration and rinsed with water and air-dried under vacuum to generate compound 4 (1,679, 4.31 mmoles, 83% yield) which was taken to the next step without further purification. LCMS ESI: calculated for C17H21N7O, a = 388.2 (M + H ”*), found 388.1 (M + H *). * H NMR (400 MHz, CHLOROPHORM-d) 5 9.20 (d,
    [00136] [00136] A stirred solution of compound 4 (1.06 g, 2.64 mmol) in THF (10 ml) was treated dropwise with aluminum and lithium hydride (1.0 M in THF, 3.96 ml, 3 , 96 mmoles) at 0 ° C. After stirring for 3 h, LCMS indicated that the reaction was complete. Na2SO4 * 10H20 was added and the reaction mixture was stirred for 1h at RT. The solid was filtered and rinsed with MeOH and the filtrate was concentrated. The crude product was purified on a 40g silica column, eluted with 20% MeOH in DCM (0-40% gradient). The desired fractions were concentrated to generate compound 5 (487 mg, 1.355 mmol, 51.3% yield). LCMS ESI: calculated for Ci6H21N7O3 = 359.2 (M + H *), found 360.1 (M + H *), * H NMR (400 MHz, DMSO-ds) 5 9.91 (s, 1H) , 8.48 (d, J = 5.5 Hz, 2H), 6.68 - 6.00 (m, 2H), 4.96 (s, 2H), 4.52 (s, 2H), 4, 01 (t, J = 6.6 Hz, 2H), 1.58 - 1.42 (m, 2H), 1.32 - 1.19 (m, 2H), 0.80 (t, J = 7, 4 Hz, 3H).
    [00137] [00137] Compound 5 (12.7 mg, 0.035 mmol) was dissolved in 0.5 ml THF and 1.0 M HCI (1.0 ml). After stirring at 60ºC for 3 h, the reaction was completed. The reaction mixture was concentrated. The crude product was purified on a 15.5g C18 Aq column, eluting with 0.05% TFA in acetonitrile: 0.05% TFA in H2O (0-50% gradient) to generate compound 6 ( 4.0 mg, 10.89 umoles, 10.54% yield). LCMS ESI: calculated for C1sHi9N7O3 = 346.2 (M + H *), found 346.1 (M + H *), * H NMR (400 MHz, DMSO-ds) 5 9.91 (s, 1H) , 8.48 (d, J = 5.5 Hz, 2H), 6.68 - 6.00 (m, 2H), 4.96 (s, 2H), 4.52 (s, 2H), 4, 01 (t, J = 6.6 Hz, 2H), 1.58 - 1.42 (m, 2H), 1.32 - 1.19 (m, 2H), 0.80 (t, J = 7, 4 Hz, 3H).
    [00138] [00138] A suspension of compound 6 (120 mg, 0.347 mmol) in THF (2 ml) was treated with thionyl chloride (0.254 ml, 3.47 mmol) at
    [00139] [00139] “A solution of compound 7 (10 mg, 0.027 mmol) in N, N-Dimethylformamide (DMF, 1 ml) was treated with cyclobutanamine (0.012 ml, 0.137 mmol) and then stirred at 60 ° C for 1 h . LCMS indicated that the reaction was complete. The reaction mixture was then purified on a 15.5g C18 Aq column, eluting with 0.05% TFA in acetonitrile: 0.05% TFA in H2O (0-50% gradient) to generate compound la-08 (3.7 mg, 9.10 umoles, 33.1% yield). LCMS ESI: calculated for CisH26N8O2 = 397.2 (MH *), found 397.2 (M- H *), * H NMR (400 MHz, METANOL-ds) 5 8.65 (s, 1H), 8.56 (s , 1H), 5.21 (s, 2H), 4.22 (t, J = 6.5 Hz, 2H), 3.99 (s, 2H), 3.54 - 3.42 (m, 2H) , 2.28 - 2.18 (m, 2H), 2.00 - 1.89 (m, 2H), 1.84 - 1.65 (m, 4H), 1.53 - 1.41 (m, 3H), 0.97 (t, J = 7.4 Hz, 4H).
    [00140] [00140] “In general following the procedure above and using alternative amines for cyclobutanamine, additional compounds according to formula (la) were prepared, as listed in Table D below.
    [00141] [00141] - Despite having been used in the scheme of Figure 1 as a synthetic intermediate, compound 6 also has TLR7 agonist activity, with an ECs5o of 288 nM. NH (6)
    [00142] [00142] This example and Figure 2 refer to the synthesis of compounds according to formula (lc).
    [00143] [00143] To a solution of dimethyl pyridine-2,5-dicarboxylate 8 (CAS Reg. No. 881-86-7, 5 g, 25.6 mmoles) in THF (50 ml) / MeOH (100 ml), calcium chloride (11.37 g, 102 mmol) was added. The reaction mixture was sonicated for 5 min and cooled to 0ºC. Sodium boron powder (2.423 g, 64.0 mmoles) was added slowly (gas evolution). The mixture was stirred at 0ºC for 2 h, after which LCMS showed the completion of the reaction. The reaction was cooled suddenly
    [00144] [00144] A solution of compound 9 (2.5 g, 14.96 mmoles) in DMF (10 ml) was treated with imidazole (1.527 g, 22.43 mmoles) and t-butyldimethylsilyl chloride (TBS-CI , 2.480 g, 16.45 mmoles). After 2h, LCMS showed the completion of the reaction. The reaction was washed with NaHCO; sat. aq. and brine, and the organic layer was dried over Na2SO4. The crude methyl 6 - (((tert-butyldimethylsilyl)) oxymethyl) nicotinate (93% yield) was taken to the next step without further purification.
    [00145] [00145] “A solution of the crude methyl 6 - (((tert-butyldimethylsilyl) oxy) methyl) nicotinate (3.9 g, 13.86 mmoles) in THF (50 ml) was cooled to 0ºC and treated dropwise with a solution of Red-Al'TY (sodium bis (2-methoxyethoxy) aluminum hydride solution, 10.37 ml, 31.9 mmoles). The reaction was stirred for 30 min, after which LCMS showed the completion of the reaction. The reaction was quenched by dropping MeOH (10 ml) followed by 1 M NaOH solution (20 ml). The mixture was stirred for 20 min. The layers were separated and the aqueous layer was extracted with EtOAc 3 times. The concentration of organic phases provided the desired (6 - (((tert-butyldimethylsilyl) oxy) Methyl) pyridin-3-yl) methanol as a yellowish liquid (97% yield).
    [00146] [00146] A mixture of the previous product (3.4 g, 13.42 mmoles) and triphenylphosphine (3.87 g, 14.76 mmoles) in DCM (50 ml) was slowly treated with N-bromosuccinimide (NBS, 2, 63 g, 14.76 mmoles) and stirred for 30 min. LCMS showed the completion of the reaction. The solvent was evaporated and the crude product was purified on 80 g of golden silica gel eluting with 0-50% EtOAc / hexane to provide compound 10 as a white solid (75% yield). LCMS ESI calculated for
    [00147] [00147] A mixture of compound 11 (CAS Reg. No. 473930-51-7, 1.906 g, 9.20 mmoles), compound 10 (3.2 g, 10.12 mmoles) and cesium carbonate (3 , 30 g, 10.12 mmoles) in DMF (20 ml) was heated to 70ºC for 5 h, after which LCMS showed the completion of the reaction. The reaction was filtered to remove the cesium carbonarto and the filtrate was diluted with EtOAc (50ml). The organic layer was washed with water (2x50 ml) and brine (2x50 ml). The solvent was evaporated and the crude product was purified on an 80 g golden silica gel column eluting with 0-50% MeOH / DCM to generate compound 12 as a white solid (56% yield). * H NMR (400 MHz, Chloroform-d) 5 8.45 (d, J = 2.2 Hz, 1H), 7.55 (dd, J = 8.1, 2.3 Hz, 1H), 7, 51 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 5.50 (s, 1H), 5.17 (s, 2H), 4.71 (s, 2H), 4.24 (t, J = 6.6 Hz, 2H), 1.74 - 1.63 (m, 2H), 1.47 - 1.33 (m, 2H), 0.85 (d, J = 12.3 Hz, 12H), 0.00 (s, 6H). LCMS ESI: calculated for Cr2H3aN6O2Si = 442.2 (M + H *), found 443.2 (M + H *).
    [00148] [00148] “A solution of compound 12 (2.0 g, 4.52 mmoles) and sodium acetate (1.853 g, 22.59 mmoles) in CHCI3 (20 ml / THF (10 ml) at 0ºC) was treated with drops of bromine (0.466 ml, 9.04 mmoles). After 30 min, LCMS showed the completion of the reaction. The reaction was quenched with 10% aq. sodium thiosulfate solution and extracted with DCM. it was evaporated to give the desired brominated intermediate as a white solid.
    [00149] [00149] A solution of the previous brominated intermediate (1.7 9, 3.26 mmoles) in MeOH (20 ml) was treated with lithium methanolate (1.238 g, 32.6 mmoles) and heated to 60 ° C overnight. LCMS showed the displacement of bromide and removal of the TBS group. The solvent was evaporated and the crude product was taken to the next step without further purification.
    [00150] [00150] A solution of the product from the previous reaction (1.168 g, 3.26 mmoles) in MeOH (5 ml) was treated with HCI in water (8.15 ml, 48.9 mmoles). The reaction mixture was heated to 60 ° C overnight. LCMS showed the completion of the reaction. The solvent was evaporated and the residue was treated with HCl in water (8.15 ml, 48.9 mmoles). The mixture was heated to 60ºC for 2 h and was neutralized with 10 M aqueous NaOH. The product precipitated and was washed with water and dried under high vacuum to give compound 13 as a white solid (47% yield in 3 steps). * H NMR (400 MHz, DMSO-d6) 5 10.04 (s, 1H), 8.39 (d, J = 2.2 Hz, 2H), 7.62 (dd, J = 8.0, 2 , 3 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 6.42 (s, 3H), 5.30 (s, 2H), 4.80 (s, 4H), 4.45 (d, J = 4.3 Hz, 4H), 4.07 (t, J = 6.6 Hz, 4H), 1.62 - 1.49 (m, 4H), 1.38 - 1 , 24 (m, 4H), 0.84 (t, J = 7.4 Hz, 6H). LCMS ESI: calculated for Ci6H20N6O3 = 344.06 (M + H *), found 34.1 (M + H *).
    [00151] [00151] A solution of compound 13 (240 mg, 0.697 mmol) in THF (1 ml) was treated with thionyl chloride (0.127 ml, 1.742 mmol). The suspension was sonicated for 30 min. LCMS showed the completion of the reaction. The solvent was evaporated and the crude product 14 (quantitative yield) was taken to the next step.
    [00152] [00152] A solution of crude product 14 (10 mg, 0.028 mmol) in DMF (0.5 ml) was treated with cyclobutanamine (9.80 mg, 0.138 mmol) in a sealed tube, which was then heated to 70ºC for 30 min. LCMS showed the completion of the reaction. The crude product was directly injected into a Shimadzu prep HPLC column with xBridge PrepC18 5 19x150 mm and eluted with 0-95% MeCN / H20 (0.1% TFA) and the product containing fractions was lyophilized to provide the compound Ic- 04 (30% yield, 4.5 mg, 10.76 umoles, 39.0% yield) as a white solid. * H NMR (400 MHz, DMSO-d6) 5 8.38 (d, J = 2.2 Hz, 1H), 7.57 (dd, J = 8.0, 2.3 Hz, 1H), 7, 29 (d, J = 8.0 Hz, 1H), 6.50 (s, 2H), 4.79 (s, 2H), 4.07 (t, J = 6.6 Hz, 2H), 3, 58 (s, 2H), 3.06 (p, J = 7.5 Hz, 1H), 1.96 (ddt, J = 10.6, 8.3, 4.4 Hz, 2H), 1.65 - 1.37 (m,
    [00153] [00153] “In general following the procedure above and using alternative amines for cyclobutanamine, additional compounds according to formula (lc) were prepared, as listed in Table E below. Table E - Additional Compounds (lc) Mass spectrum Compound, Amine Number Specific mass | Observed mass (M + H) observed (M + H)
    [00154] [00154] Compounds according to the formula (lb) were prepared in a manner analogous to the methods for preparing compounds (1c), but using chloride 17 as an intermediate. The synthesis of chloride 17 is shown schematically in Figure 3, starting with the commercially available compound (CAS Reg. No. 49668-90-8), proceeding in a similar way to the previous example, but mutatis mutandis.
    [00155] [00155] Analytical data for compounds according to the formula (lb) are provided in Table F below.
    [00156] [00156] This example describes a method for testing the TLR7 agonist activity of the compounds disclosed in this description.
    [00157] [00157] Manipulated human embryonic kidney blue cells (HEK-Blue "Y TLR cells; Invivogen) having an embryonic alkaline phosphatase reporter transgene secreted by human TLR7 (SEAP) were suspended in a non-selective culture medium (high DMEM) glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sig-
    [00158] [00158] “A representative ECso test curve for the compound (la-09) is shown in Figure 6. Example 5 - IL-6 induction
    [00159] [00159] This example describes a method for testing the induction of interleukin 6 by compounds disclosed in this description.
    [00160] [00160] Compounds diluted in DMSO were transferred to individual wells of a transparent plate, with V-bottom, of 384 wells from Matrix Technologies using ECHO acoustic liquid handling technology (25 nL per well). Samples of human whole blood (25 µL) were added to each well using a CyBio FeliX liquid handling instrument. The plate was shaken on a plate shaker for three minutes before incubating the reaction mixtures at 37ºC for 20 h. The basal RPMI 1640 medium (supplemented with L-glutamine) was then added to each well (25 µl per well) before the plasma was released from each sample by centrifugation (450 x g, 5 min, room temperature). The treated plasma samples (3 µL) were subsequently transferred to individual wells of a white, shallow 384-well ProxiPlate.
    [00161] [00161] The following procedure can be used for transglutaminase-mediated conjugation of agonist-ligand compounds in which the ligand has an amine group that can act as an amine donor. The antibody can be one that has a transglutaminase-reactive glutamine, for example, one with an N297A or N297Q substitution. Conjugation is performed by recombinant bacterial transglutaminase with an antibody: enzyme molar ratio of 5: 1. Conjugation is performed using standard protocols in 50 mM Tris buffer, pH 8.0, incubated overnight at 37ºC. The resulting conjugate is purified on a protein A column, pre-equilibrated with 50 mM Tris, pH 8.0. The conjugate is eluted with 0.1 M sodium citrate buffer, pH 3.5. The eluted fractions are neutralized with 1M Tris pH 9.0. The conjugate can be formulated in 20 mg / ml sorbitol, 10 mg / ml glycine, pH 5.0.
    [00162] [00162] The detailed description of the above invention includes passages that are mainly or exclusively related to particular parts or aspects of the invention. It should be understood that this is for clarity and convenience, that a specific feature may be relevant to more than just the passage in which it is disclosed, and that the disclosure here includes all appropriate combinations of information.
    [00163] [00163] Furthermore, although the present invention has been described in particular in terms of certain preferred embodiments, the invention is not limited to those preferred embodiments. Instead, the scope of the invention is defined by the appended claims. REFERENCES
    [00164] [00164] Complete citations for the following references cited in an abbreviated form by the first author (or inventor) and previous data in this description are provided below. Each of these references is hereby incorporated by reference for all purposes.
    Akinbobuyi et a /., ACS 2013 69th Southwest Regional Monitoring, Abstract SWRM-70, "Synthesis and evaluation of purine-based toll-like receptor 7 agonists and their antibody conjugates." Akinbobuyi et a /., ACS 2015 Joint Southeastern / Southwest Regional Meeting, Abstract 392, "Synthesis of functionalized purine analogs for antibody conjugation" [2015a].
    Akinbobuyi et al., Tetrahedron Lett. 2015, 56, 458, "Facile syntheses of functionalized toll-like receptor 7 agonists" [2015b].
    Akinbobuyi et al., Bioorg. Med. Chem. Lett. 2016, 26, 4246, "Synthesis and immunostimulatory activity of substituted TLR7 agonists." Barberis et a /., US 2012/0003298 A1 (2012).
    Beesu et al., J. Med. Chem. 2017, 60, 2084, "Identification of High-Potency Human TLR8 and Dual TLR7 / TLR8 Agonists in Pyri-
    midine-2 4-diamines. "Berghõôfer et al., J. Immunol. 2007, 178, 4072," Natural and Synthetic TLR7 Ligands Inhibit CpG-A- and CpG-C-Oligodeoxynucleotide-Induced IFN-a Production. " Bonfanti et al., US 2014/0323441 A1 (2015) [2015a].
    Bonfanti et al., US 2015/0299221 A1 (2015) [2015b].
    Carson et al., US 2013/0202629 A1 (2013).
    Carson et al., US 8,729,088 B2 (2014).
    Carson et al., US 9,050,376 B2 (2015).
    Carson et al., US 2016/0199499 A1 (2016).
    Chan et al., Bioconjugate Chem. 2009, 20, 1194, "Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates." Chan et al., Bioconjugate Chem. 2011, 22, 445, "Synthesis and Characterization of PEGylated Toll Like Receiver 7 Ligands." Cortez et al., US 2017/0044168 A1 (2017). [2017a].
    Cortez et al., US 2017/0121421 A1 (2017). [2017b].
    Desai et a /., US 9,127,006 B2 (2015).
    Ding et al., WO 2016/107536 A1 (2016).
    Ding et al., US 2017/0273983 A1 (2017) [2017a].
    Ding et al., WO 2017/076346 A1 (2017) [2017b].
    Gadd et al., Bioconjugate Chem. 2015, 26, 1743, "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Spe- cificity." Graupe et a /., US 8,993,755 B2 (2015).
    Halcomb et a /., US 9,161,934 B2 (2015).
    Hashimoto et a /., US 2009/0118263 A1 (2009).
    Hirota et al., US 6,028,076 (2000).
    Holldack et a /., US 2012/0083473 A1 (2012).
    Isobe et a /., US 6,376,501 B1 (2002).
    Isobe et al., JP 2004137157 (2004).
    Isobe et al., J. Med. Chem. 2006, 49 (6), 2088, "Synthesis and Biological Evaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers." Isobe et al., US 7,521,454 B2 (2009) [2009a].
    Isobe et al /., US 2009/0105212 A1 (2009) [2009b].
    Isobe et al., US 2011/0028715 A1 (2011).
    Isobe et al., US 8,148,371 B2 (2012).
    Jensen et al., WO 2015/036044 A1 (2015).
    Kasibhatla et a /., US 7,241,890 B2 (2007).
    Koga-Yamakawa et al., Int. J. Cancer 2013, 132 (3), 580, "Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer." Li et al., US 9,902,730 B2 (2018).
    Lioux et a /., US 9,295,732 B2 (2016).
    Lund et al., Proc. Nat'l Acad. Sci (USA) 2004, 101 (15), 5598, "Recognition of single-stranded RNA viruses by Toll-like receptor 7 Maj et a /., US 9,173,935 B2 (2015).
    McGowan et al., J. Med. Chem. 2017, 60, 6137, "Identification and Optimization of Pyrrolo [3,2-d] pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B." Musmuca et al., J. Chem. Information & Modeling 2009, 49 (7), 1777, "Small-Molecule Interferon Inducers. Toward the Comprehension of the Molecular Determinants through Ligand-Based Apaches." Ogita et a /., US 2007/0225303 A1 (2007).
    Peterson, Rachel; Honor Program Thesis, "Synthesis of South-
    fur and Amino-8-Substituted Adenine Derivatives as TLR7 Agonists, "Baylor University (2014).
    Pryde, US 7,642,350 B2 (2010).
    Roethle et al., J. Med. Chem 2013, 56, 7324, "Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis." Seifert, Zacharie; Master of Science Thesis, "Synthesis and Evaluation of 8-Substituted Adenine Derivatives as Toll-like Receptor 7 Agonists," Baylor University (2015).
    Vernejoul et a /., US 2014/0141033 A1 (2014).
    Yu et al., PLoS One 2013, 8 (3), and 56514, "Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies." Zhang et al., Immunity 2016, 45, 737, "Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA." Zurawski et a /., US 2012/0231023 A1 (2012).
    权利要求:
    Claims (20)
    [1]
    1. A compound characterized by the fact that it has a structure according to formula (1) NH mm
    NOS N Loo Air where Ar is NT Re 5a Reno Nisa REONÔORER SR; Ns No. R R R | of R2 Rô E A, O R , RN "R, or RA ONOTR; R 'is (C1-C5 alkyl) O, (C1-C2 alkyl) O (CH2) 2.30, (C1-Cs alkyl) C (= O) O, (C1- C5 alkyl) | NH, (C1-C2 alkylJO (CH2) 2-3aNH, or (C1-C5 alkylJO (= O) NH; R 'is, independently for each occurrence of the same, H, C1-C; 3 alkyl, halo, O (C1-C; 3 alkyl), CN, or NO; z; and R 'and Rº are independently H; C1-Cs alkyl; (CH2) 2- 40H; (CH2) 2-40 (C1 -C3 alkyl); (CH2) 2-4NH2; (CH2) 2-4NH (C1-C3 alkyl); (CH2) 2-4N (C1-C3 alkyl)> .; (CH2) 1-3 (aryl); (CH2) 1-3 (heteroaryl); (CH2) 2- a (OCH2CH2) 2-8 (CH2) 2-4NHBoc; | <CHiases in which a CH> 2 group on the cyclo-lifatic ring can be replaced by O, S, NH, or N (C1-C3 alkyl) and the cycloaliphatic ring can be replaced with C1-C3 alkyl, OH, O (C1-C; 3 alkyl), halo, (CH2) o-3NH2, or ( CH2) o-3NH (C1-C3 alkyl); or R3 and Rº combine with the nitrogen to which they are attached to form a cyclic amine of the ENOCHidos structure, in which a CH> 2 group in the cycloaliphatic ring that is separated from the amine nitrogen by at least two CH groups> 2 can be s substituted by O, S, NH, or N (C1-C; 3 alkyl) and the cyclic amine can be replaced by C1-C3 alkyl, OH, O (C1-C3 alkyl), halo, (CH2) o-3NH> 2, or (CH2) o-aNH (C1-C; 3 alkyl).
    [2]
    2. Compound, according to claim 1, characterized by the fact that —-N (Rº) (Rº) is
    FAN LO us n o q o d o Nine
    H H No Me, H KH N x N N NW, kh DÃO,
    H H H H CN Me NX “Me Mor Nor yu NH>
    RO TD VI Me x Me NH> NH, x SS, or
    H NS Og O o NHBoe
    [3]
    3. Compound according to claim 1, characterized by the fact that it has a structure represented by the formula (la): NH (la) ES -os |
    RN N at Ng node
    [4]
    4. Compound, according to claim 3, characterized by the fact that -N (R3) (Rº) is
    FAN LO us n o q o dd RA x Nine
    H H No Me, H KH N x N N XV, and OO, N me QN N N CAME Nvme KIiMoH> Mor yu NH> DX we X XX ve NH> NH, x SS, or
    H NS Og O o NHBoe
    [5]
    5. Compound according to claim 4, characterized by the fact that, in the formula (la), R 'is n-BuO.
    [6]
    6. Compound according to claim 1, characterized by the fact that it has a structure represented by the formula (lb): NH (lb)
    NOSTN Ox XY oH RN - No Re
    DAN
    [7]
    7. Compound according to claim 6, characterized by the fact that —-N (Rº) (Rº) is
    FAN
    LO N P O N x SS RA xo Nine
    H H NoMe O KH N x N N XV, ke OO, NV me QN N N oO "x Me Xv MoH XX Mor yu NH> D de x Toe
    NH> NH, XxX, XxX, OR
    H NS Og O o NHBoe
    [8]
    8. Compound according to claim 7, characterized by the fact that, in formula (Ib), R 'is n-BuO.
    [9]
    9. Compound according to claim 1, characterized by the fact that it has a structure represented by the formula (lc): NH (lc) ES os |
    RN N ot 1 Ne N ps |
    [10]
    10. Compound, according to claim 9, characterized by the fact that —-N (R $) (Rº) is
    FAN H | H O O H SO RA x Name
    H H NMe À N N x N N XV, e XD, NV me QN N N oO "x Me Xv MoH XX Mor yu NH> D de x Toe NH> NH> x, x, OR
    H SO Na O NHBoe
    [11]
    11. Compound according to claim 10, characterized by the fact that, in formula (lc), R 'is n-BuO.
    [12]
    12. Compound, characterized by the fact that it has a structure according to the formula (7): NH> (7) OE S-os neu Né N
    N “A AA ALe
    [13]
    13. Compound, characterized by the fact that it has a structure according to formula 14: NH>
    NORN Xd-os n-Buo ”" NODE TN Í Dx 14 Ne
    [14]
    14. Compound, characterized by the fact that it has a structure according to formula 17: NH>
    NOR N Ox S-oH neu Né N
    N ace Du 17
    [15]
    15. Compound according to claim 1, characterized by the fact that it is conjugated to an antibody.
    [16]
    16. Compound according to claim 1, characterized by the fact that it is covalently linked to a portion of poly (ethylene glycol) between 2 kDa and 40 kDa in size.
    [17]
    17. Compound according to claim 1, characterized by the fact that it is to treat a condition that can be treated by activation of the Toll-like receptor 7.
    [18]
    18. Composition, characterized by the fact that it comprises a compound as defined in any one of claims 1 to
    17.
    [19]
    19. Use of a compound as defined in any one of claims 1 to 17, characterized by the fact that it is for the preparation of a composition to treat a condition amenable to treatment by activation of the Toll 7 type receptor.
    [20]
    20. Invention, characterized by any of its embodiments or any applicable claim categories, for example, product, process or use, encompassed by the material initially disclosed, described or illustrated in the patent application.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112020002957A2|2020-08-04|6-amino-7,9-dihydro-8h-purin-8-one derivatives as toll 7 | receptor agonists as immunostimulants
    ES2887253T3|2021-12-22|6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulatory agonists of toll-like receptor 7 |
    EP3668872B1|2022-02-23|6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulant toll-like receptor 7 | agonists
    EP3668870B1|2021-12-08|6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulant toll-like receptor 7 | agonists
    EP3668868B1|2021-09-22|Toll-like receptor 7 | agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
    同族专利:
    公开号 | 公开日
    AU2018317857A1|2020-04-02|
    JP2020531474A|2020-11-05|
    CA3072708A1|2019-02-21|
    SG11202001254XA|2020-03-30|
    EP3668869B1|2022-01-12|
    US10494370B2|2019-12-03|
    EP3668869A1|2020-06-24|
    WO2019035968A1|2019-02-21|
    US20200308175A1|2020-10-01|
    TW201920182A|2019-06-01|
    US10919895B2|2021-02-16|
    IL272631D0|2020-03-31|
    AR112688A1|2019-11-27|
    KR20200041913A|2020-04-22|
    US20190055245A1|2019-02-21|
    EA202090410A1|2020-08-06|
    US10723736B2|2020-07-28|
    US20200048255A1|2020-02-13|
    CN110997673A|2020-04-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1981001145A1|1979-10-18|1981-04-30|Univ Illinois|Hydrolytic enzyme-activatible pro-drugs|
    US4698420A|1985-02-25|1987-10-06|Xoma Corporation|Antibody hybrid molecules and process for their preparation|
    US6214345B1|1993-05-14|2001-04-10|Bristol-Myers Squibb Co.|Lysosomal enzyme-cleavable antitumor drug conjugates|
    JP4667543B2|1996-07-03|2011-04-13|大日本住友製薬株式会社|New purine derivatives|
    TW572758B|1997-12-22|2004-01-21|Sumitomo Pharma|Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives|
    US7425541B2|1998-12-11|2008-09-16|Medarex, Inc.|Enzyme-cleavable prodrug compounds|
    KR20020047132A|1999-08-24|2002-06-21|메다렉스, 인코포레이티드|Human ctla-4 antibodies and their uses|
    US7402556B2|2000-08-24|2008-07-22|Medarex, Inc.|Prodrugs activated by plasmin and their use in cancer chemotherapy|
    AT404561T|2001-04-17|2008-08-15|Dainippon Sumitomo Pharma Co|NEW ADENINE DERIVATIVES|
    CN1463270A|2001-05-31|2003-12-24|梅达莱克斯公司|Disulfide prodrugs and linkers and stablizers useful therefore|
    CA2450316A1|2001-06-11|2002-12-19|Medarex, Inc.|Cd10-activated prodrug compounds|
    US7091186B2|2001-09-24|2006-08-15|Seattle Genetics, Inc.|p-Amidobenzylethers in drug delivery agents|
    US7241890B2|2001-10-30|2007-07-10|Conforma Therapeutics Corporation|Purine analogs having HSP90-inhibiting activity|
    EP1471938A4|2002-01-09|2008-03-05|Medarex Inc|Human monoclonal antibodies against cd30|
    KR101111085B1|2002-09-27|2012-04-12|다이닛본 스미토모 세이야꾸 가부시끼가이샤|Novel adenine compound and use thereof|
    JP2004137157A|2002-10-16|2004-05-13|Sumitomo Pharmaceut Co Ltd|Medicine comprising new adenine derivative as active ingredient|
    JP4753867B2|2003-04-15|2011-08-24|グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー|Conjugates containing human IL-18 and substitutional variants thereof|
    PE20050712A1|2003-07-22|2005-11-02|Schering Ag|RG1 ANTIBODIES|
    WO2005051976A2|2003-11-20|2005-06-09|Ansata Therapeutics, Inc.|Protein and peptide ligation processes and one-step purification processes|
    PT1691837E|2003-12-10|2012-08-27|Medarex Inc|Ip-10 antibodies and their uses|
    US7375078B2|2004-02-23|2008-05-20|Genentech, Inc.|Heterocyclic self-immolative linkers and conjugates|
    CA2561264A1|2004-03-24|2005-10-06|Xencor, Inc.|Immunoglobulin variants outside the fc region|
    EP1728792A4|2004-03-26|2010-12-15|Dainippon Sumitomo Pharma Co|8-oxoadenine compound|
    US7691962B2|2004-05-19|2010-04-06|Medarex, Inc.|Chemical linkers and conjugates thereof|
    US7714016B2|2005-04-08|2010-05-11|Medarex, Inc.|Cytotoxic compounds and conjugates with cleavable substrates|
    CA2564076C|2004-05-19|2014-02-18|Medarex, Inc.|Chemical linkers and conjugates thereof|
    AU2005286607B2|2004-09-23|2011-01-27|Genentech, Inc.|Cysteine engineered antibodies and conjugates|
    RU2421466C2|2005-02-18|2011-06-20|Медарекс, Инк.|Recovered prostate specific membrane antigen antibody and method of inhibition of psma-expressing cell growth|
    PL1851250T3|2005-02-18|2012-10-31|Squibb & Sons Llc|Human monoclonal antibody to prostate specific membrane antigen |
    BRPI0611435A2|2005-05-04|2010-09-08|Pfizer Ltd|2-starch-6-amino-8-oxopurine derivatives, pharmaceutical compositions, use and process for preparing same|
    EP3530736A3|2005-05-09|2019-11-06|ONO Pharmaceutical Co., Ltd.|Human monoclonal antibodies to programmed death 1 and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics|
    MX2007015944A|2005-06-20|2008-03-07|Medarex Inc|Cd19 antibodies and their uses.|
    US8302735B2|2005-06-29|2012-11-06|Sky Climber, Llc|Self-erecting suspension platform system|
    CA2612241C|2005-07-01|2018-11-06|Medarex, Inc.|Human monoclonal antibodies to programmed death ligand 1 |
    ES2649550T3|2005-07-18|2018-01-12|Seattle Genetics, Inc.|Beta-glucuronide drug linker conjugates|
    JP2010500885A|2006-08-18|2010-01-14|ノボノルディスクヘルスケアアーゲー|Transglutaminase variants with improved specificity|
    WO2007034817A1|2005-09-22|2007-03-29|Dainippon Sumitomo Pharma Co., Ltd.|Novel adenine compound|
    US20090105212A1|2005-09-22|2009-04-23|Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan|Novel adenine compound|
    NZ566395A|2005-09-26|2012-03-30|Medarex Inc|Human monoclonal antibodies to CD70|
    AU2006294554B2|2005-09-26|2013-03-21|E. R. Squibb & Sons, L.L.C.|Antibody-drug conjugates and methods of use|
    BRPI0619331A2|2005-10-26|2011-09-27|Medarex Inc|method for making a compound to prepare a cbi cc-1065 analog, method for making a cbi cc-1065 analog and compound|
    WO2007059404A2|2005-11-10|2007-05-24|Medarex, Inc.|Duocarmycin derivatives as novel cytotoxic compounds and conjugates|
    JP5714212B2|2005-12-08|2015-05-07|メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ．|Human monoclonal antibody against O8E|
    RS52804B|2005-12-08|2013-10-31|Medarex Inc.|Human monoclonal antibodies to protein tyrosine kinase 7 and their use|
    JP5620100B2|2006-06-29|2014-11-05|ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー|Method for cell-free synthesis of proteins containing unnatural amino acids|
    WO2008102008A1|2007-02-22|2008-08-28|Novo Nordisk Health Care Ag|Transglutaminase variants with improved specificity|
    JP2010502221A|2006-09-08|2010-01-28|アンブルックス，インコーポレイテッド|Site-specific incorporation of unnatural amino acids by vertebrate cells|
    HUE033630T2|2006-10-02|2017-12-28|Squibb & Sons Llc|Human antibodies that bind CXCR4 and uses thereof|
    KR101552735B1|2006-12-01|2015-09-14|메다렉스, 엘.엘.시.|22 human antibodies that bind cd22 and uses thereof|
    UY30776A1|2006-12-21|2008-07-03|Medarex Inc|CD44 ANTIBODIES|
    TWI412367B|2006-12-28|2013-10-21|Medarex Llc|Chemical linkers and cleavable substrates and conjugates thereof|
    HUE025555T2|2007-02-07|2016-02-29|Univ California|Conjugates of synthetic tlr agonists and uses therefor|
    EP2121667B1|2007-02-21|2016-06-08|E. R. Squibb & Sons, L.L.C.|Chemical linkers with single amino acids and conjugates thereof|
    AR065784A1|2007-03-20|2009-07-01|Dainippon Sumitomo Pharma Co|DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.|
    EA024359B1|2007-06-29|2016-09-30|Джилид Сайэнс, Инк.|Purine derivatives and their use as modulators of toll-like receptor 7|
    EP2185188B1|2007-08-22|2014-08-06|Medarex, L.L.C.|Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions|
    US8268970B2|2007-10-01|2012-09-18|Bristol-Myers Squibb Company|Human antibodies that bind mesothelin, and uses thereof|
    WO2010018134A1|2008-08-11|2010-02-18|Smithkline Beecham Corporation|Novel adenine derivatives|
    AR074506A1|2008-12-09|2011-01-19|Gilead Sciences Inc|TOLL TYPE RECEIVERS MODULATORS|
    US8940501B2|2009-01-30|2015-01-27|Whitehead Institute For Biomedical Research|Methods for ligation and uses thereof|
    CN102439011B|2009-02-11|2016-05-04|加利福尼亚大学校务委员会|The treatment of TOLL sample receptor modulators and disease|
    SG10201406813RA|2009-10-22|2014-11-27|Gilead Sciences Inc|Derivatives of purine or deazapurine useful for the treatment of viral infections|
    WO2011079016A1|2009-12-22|2011-06-30|Gilead Sciences, Inc.|Methods of treating hbv and hcv infection|
    WO2011139348A2|2010-04-30|2011-11-10|The Regents Of The University Of California|Uses of phospholipid conjugates of synthetic tlr7 agonists|
    US20120003298A1|2010-04-30|2012-01-05|Alcide Barberis|Methods for inducing an immune response|
    EP2563404B1|2010-04-30|2016-09-21|Urogen Pharma Ltd.|Phospholipid drug analogs|
    WO2012038058A1|2010-09-21|2012-03-29|Telormedix Sa|Treatment of conditions by toll-like receptor modulators|
    EP2635310A2|2010-11-05|2013-09-11|Rinat Neuroscience Corp.|Engineered polypeptide conjugates and methods for making thereof using transglutaminase|
    WO2012122396A1|2011-03-08|2012-09-13|Baylor Research Institute|Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells|
    KR20140050698A|2011-07-29|2014-04-29|셀렉타 바이오사이언시즈, 인크.|Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte immune responses|
    DK2776439T3|2011-11-09|2018-10-22|Janssen Sciences Ireland Uc|PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS|
    SI2872515T1|2012-07-13|2016-10-28|Janssen Sciences Ireland Uc|Macrocyclic purines for the treatment of viral infections|
    WO2014075392A1|2012-11-16|2014-05-22|Merck Sharp & Dohme Corp.|Purine inhibitors of human phosphatidylinositol 3-kinase delta|
    EP2732825B1|2012-11-19|2015-07-01|Invivogen|Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist|
    RS56169B1|2013-02-14|2017-11-30|Bristol-Myers Squibb Company|Tubulysin compounds, methods of making and use|
    US9295732B2|2013-02-22|2016-03-29|Invivogen|Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists|
    US20160199499A1|2013-08-16|2016-07-14|The Regents Of The University Of California|Uses of phospholipid conjugates of synthetic tlr7 agonists|
    WO2015036044A1|2013-09-13|2015-03-19|Telormedix Sa|Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood|
    PE20170325A1|2014-05-01|2017-04-21|Novartis Ag|COMPOUNDS AND COMPOSITIONS AS AGONISTS OF THE TOLL-TYPE RECEPTOR|
    BR112016025048A2|2014-05-01|2017-10-31|Novartis Ag|compounds and compositions as toll7 receptor agonists|
    SG10201809918RA|2014-08-15|2018-12-28|Chia Tai Tianqing Pharmaceutical Group Co Ltd|Pyrrolopyrimidine compounds used as tlr7 agonist|
    CN105732635A|2014-12-29|2016-07-06|南京明德新药研发股份有限公司|Toll-like receptor 7 agonist|
    EP3268048B1|2015-03-10|2019-05-08|Bristol-Myers Squibb Company|Antibodies conjugatable by transglutaminase and conjugates made therefrom|
    KR20180055889A|2015-10-02|2018-05-25|브리스톨-마이어스 스큅 컴퍼니|Transglutaminase variants for conjugating antibodies|
    MA44334A|2015-10-29|2018-09-05|Novartis Ag|ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST|
    AU2016349080B2|2015-11-05|2019-03-14|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|7- pyrrolopyrimidine compound as TLR7 agonist|
    WO2017100557A1|2015-12-11|2017-06-15|Graphic Packaging International, Inc.|Container with absorption features|KR20190026761A|2016-07-07|2019-03-13|더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티|Antibody-adjuvant conjugate|
    US20210053979A1|2018-04-24|2021-02-25|Bristol-Myers Squibb Company|Macrocyclic toll-like receptor 7agonists|
    US20200038403A1|2018-08-03|2020-02-06|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS AND METHODS AND USES THEREFOR|
    AU2019386945A1|2018-11-30|2021-07-22|Bristol-Myers Squibb Company|Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses|
    KR20210102334A|2018-12-12|2021-08-19|브리스톨-마이어스 스큅 컴퍼니|Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses|
    WO2020162705A1|2019-02-08|2020-08-13|성균관대학교산학협력단|Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same|
    WO2021154667A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154669A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154668A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154661A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154665A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154662A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154663A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154664A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    WO2021154666A1|2020-01-27|2021-08-05|Bristol-Myers Squibb Company|1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7AGONISTS|
    法律状态:
    2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    2021-11-23| B11A| Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing|
    2022-02-08| B11Y| Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]|
    优先权:
    申请号 | 申请日 | 专利标题
    US201762546195P| true| 2017-08-16|2017-08-16|
    US62/546,195|2017-08-16|
    PCT/US2018/000243|WO2019035968A1|2017-08-16|2018-08-16|6-amino-7,9-dihydro-8h-purin-8-one derivatives as toll-like receptor 7agonists as immunostimulants|
    [返回顶部]